Overview

This trial is active, not recruiting.

Condition glioblastoma multiforme
Treatments ct-322, temozolomide, radiation therapy
Phase phase 1
Sponsor Adnexus, A Bristol-Myers Squibb R&D Company
Start date October 2008
End date October 2010
Trial size 30 participants
Trial identifier NCT00768911, CT-322.003

Summary

Rationale:

In light of the demonstrated activity of anti-angiogenesis agents in rGBM, it is reasonable to postulate that adding these agents to standard RT and chemotherapy in the up-front management of newly diagnosed GBM may improve the clinical benefit. This study will examine the safety and tolerability of adding CT-322 to the standard radiation therapy/temozolomide (RT/TMZ) backbone of treatment for newly diagnosed GBM

United States No locations recruiting
Other Countries No locations recruiting

Study Design

Allocation non-randomized
Intervention model single group assignment
Masking open label
Primary purpose treatment
Arm
(Experimental)
ct-322
Intravenous solution, intravenous administration, starting dose level of 0.5 mg/kg/week Dose levels: 0.5 mg/kg/week, 1.0 mg/kg/week, 2.0 mg/kg/week
temozolomide Temodar
75 mg/M2/day p.o. continuously 7 days per week during concurrent RT (max: 49 days) 150 mg/M2/day X 5 days; adjuvant cycle #1 200 mg/M2/day X 5 days; subsequent adjuvant cycles (# 2-12) if tolerability criteria met
radiation therapy
RT will consist of fractionated focal irradiation administered using 2 Gy/fraction, QD x 5 days/week for 6 weeks, for a total dose of 60 Gy

Primary Outcomes

Measure
Evaluate the safety and tolerability of CT-322 administered in combination with standard focal brain RT/TMZ to subjects with newly diagnosed GBM
time frame: 15 ± 5 days post the last dose of study drug
Establish the recommended Phase 2 dose for the QW schedule of CT-322 for use in this combination
time frame: Every 4 weeks until MTD or 2.0 mg/kg dose level is reached

Secondary Outcomes

Measure
To describe the PK of TMZ and its active metabolite (MTIC) when TMZ is administered alone and when it is co-administered with CT-322 to a subset of approximately 12 subjects with newly diagnosed GBM
time frame: Cycle 1, day 1 of RT phase of treatment
To describe the peak and trough concentrations of CT-322 when administered alone and when co-administered with TMZ
time frame: RT phase treatment weeks 1-3, 5, 7-10, day 1. Post RT phase cycles 1-3, day 1; then day 1 every 3 cycles thereafter; EOS visit
To evaluate the immunogenicity of CT-322 when administered in combination with standard focal brain RT/TMZ to subjects with newly diagnosed GBM
time frame: RT phase treatment weeks 1, 5, 7-8, day 1. Post RT phase cycles 1 and 3, day 1; then day 1 every 3 cycles thereafter; EOS visit
To characterize the plasma biomarker response to CT-322 when administered in combination with standard focal brain RT/TMZ to subjects with newly diagnosed GBM
time frame: RT phase treatment weeks 1-3, 5, 7-8, day 1. Post RT phase cycles 1-3, day 1, then day 1 every 3 cycles thereafter; EOS visit

Eligibility Criteria

Male or female participants at least 18 years old.

Inclusion Criteria: - Informed consent - 18 years or older - Newly diagnosed, histologically confirmed GBM (grade IV astrocytoma): - Subjects will not be eligible if the original histology was a lower grade glioma and a subsequent histological diagnosis of a GBM is made - Central independent pathology confirmation of GBM, concurrent with subject enrollment - Subjects with sufficient biopsy material available to perform PCR analysis for MGMT promoter methylation must have tissue submitted to the designated laboratory for analysis. Subjects with insufficient tissue or indeterminate results will remain eligible for enrollment. - KPS ≥ 60 - Be able to begin treatment with RT/TMZ within 6 weeks after biopsy or craniotomy with satisfactory wound healing prior to initiating treatment with CT-322 - Be able to undergo serial MRIs: - Measurable or assessable disease may or may not be present - CT scanning may not substitute for MRI scanning - Have adequate bone marrow, liver, renal, and metabolic function as assessed by the following: - Hemoglobin ≥ 10.0 g/dL (unsupported) - Absolute neutrophil count (ANC) ≥ 1,500/mm3 (unsupported) - Platelet count ≥ 100,000/mm3 (unsupported) - Total bilirubin ≤ 1.5 x ULN, unless due to Gilbert's disease - ALT and AST ≤ 3 x ULN - INR < 1.5 or PT within normal limits; and PTT within normal limits - Serum creatinine ≤ 1.5 x ULN - Urine protein/creatinine ratio (UPCR) < 1.0 - Serum amylase and lipase ≤ 1.5 x the ULN - 2-dimensional echo or MUGA scan with LVEF within the institutional normal range - Stable or decreasing dose of corticosteroids for at least 1 week prior to screening MRI - Contraceptive measures for male and female participants for the duration of treatment and for 4 weeks following discontinuation of study treatment: --Female subjects having reproductive potential must have a negative serum pregnancy test within 72 hours before first administration of CT-322 - Be able to comply with scheduled visits, treatment plan, laboratory tests, and other study procedures including receiving daily external beam RT in a radiation treatment facility: - integral to or affiliated with the investigative site and in which the treating radiation therapist is a participating study investigator; and - that has agreed to follow the radiation treatment guidance and complete the radiation treatment data collection forms Exclusion Criteria: - Prior CT-322 therapy or prior therapy with another VEGF-modulating agent (marketed or investigational) for malignant glioma - History of hypersensitivity to TMZ or any of its excipients, or to Dacarbazine (DTIC) - Prior treatment for GBM, except surgical resection and/or corticosteroid therapy - Prior radiotherapeutic, or local (intra-tumoral) or systemic medical therapies (including but not limited to: chemotherapy, hormonal therapy, immunotherapy, anti-angiogenic therapy, implantable Gliadel® wafers, and molecularly targeted therapy) for brain tumors - Current enrollment in another therapeutic clinical trial involving ongoing therapy - Concurrent severe and/or uncontrolled medical disease that could compromise participation in the study such as: - Pleural or pericardial effusion of ≥ grade 2 - Uncontrolled diabetes, despite optimal medical management, according to the opinion of the investigator - Uncontrolled hypertension (defined as systolic blood pressure > 150 mmHg or diastolic pressure > 90 mmHg, despite optimal medical management) - Any active craniotomy-related wound infection - Active clinically significant infection (> grade 2 by National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events v3.0 (CTCAE) requiring the use of anti-microbial agents, or that would be otherwise, in the opinion of the investigator, interfere with the ability of the subject to participate - History of clinically significant bleeding diathesis or coagulopathy including platelet function disorder (e.g., known hemophilia or von Willebrand disease) or acquired bleeding disorder within one year (e.g., acquired anti-factor VIII antibodies) - Ongoing or recent (≤ 3 months) significant gastrointestinal bleeding untreated or recurring - Untreated peptic ulcer disease or peptic ulcer disease treated for < 3 months - Non-healing wound (including craniotomy wound), ulcer, or bone fracture; or - Glomerulonephritis or other protein-wasting glomerulopathy - Within 12 months before enrollment had: - Thrombotic or embolic cerebrovascular accident or transient ischemic attacks - CNS bleed (other than stable, grade 1) - Intraocular bleed, or any medical condition, which in the opinion of the investigator increases the risk for intra-ocular bleeding - Septic endocarditis (unless deemed cured and off all antibiotic therapy for at least 3 months) - Coronary artery bypass graft, angioplasty, vascular stenting, myocardial infarction, unstable angina; or - Symptomatic congestive heart failure (New York Heart Association ≥ class II) - Any intraparenchymal CNS hemorrhage at the time of enrollment except for: - Grade 1 intraparenchymal hemorrhage in the immediate post-operative period, or - Grade 1 intraparenchymal hemorrhage that has been stable (no significant change on 2 consecutive MRI scans at least 4 weeks apart) or improved - Subjects with a history of prior cardiotoxic chemotherapy exposure or subjects with thoracic irradiation involving cardiac tissue - Other, non-glioma related major surgery, open biopsy, or significant traumatic injury within 4 weeks before the first dose of CT-322 --Placement of subcutaneous in-dwelling venous access port within 2 weeks before the first dose of CT-322 - Known human immunodeficiency virus infection or known active acute or chronic viral hepatitis - Prior malignancy within the previous 3 years, except adequately treated basal cell skin cancer or cervical carcinoma in situ; or if the other primary malignancy is not currently clinically significant or requiring active intervention - Has any other severe, acute, or chronic medical or psychiatric condition, or laboratory abnormality that could increase the risks associated with study participation or study drug administration or could interfere with the interpretation of the study results and, in the judgment of the investigator, would make the subject inappropriate for entry in this study or non-compliant with study-related procedures - Subjects with medical conditions that would not permit, in the judgment of the investigator, the safe discontinuation of medications that are prohibited throughout the course of the study - Any condition requiring therapeutic anti-coagulation with either oral (e.g., warfarin type) or injectable anti-coagulants; however, low-dose (i.e., 1 mg daily [QD]) warfarin is permitted for venous port patency maintenance - Females who are pregnant or breast feeding.

Additional Information

Official title Phase 1, Open Label, Multi-Center Study To Evaluate The Safety And Tolerability of CT-322 Administered In Combination With Focal Brain Radiotherapy And Temozolomide To Subjects With Newly Diagnosed Glioblastoma Multiforme
Trial information was received from ClinicalTrials.gov and was last updated in October 2010.
Information provided to ClinicalTrials.gov by Adnexus, A Bristol-Myers Squibb R&D Company.